Sun Pharma Advanced Research Q2 FY27: revenue Rs 30.03 cr, loss narrows YoY

What the numbers show

• Net margin was -81.22% of revenue, against -965.01% a year earlier.
• Revenue rose 282.1% while total expenses fell 6.8%.

• Basis: Consolidated statement of unaudited financial results for the quarter ended 30.09.2026, compared with quarter ended 30.09.2025.

• Revenue from operations (Total revenue from operations): Rs 30.03 cr vs Rs 7.86 cr

• Other income: Rs 23.62 cr vs Rs 0.01 cr

• Total income: Rs 53.65 cr vs Rs 7.87 cr

• Cost of materials consumed: Rs 9.95 cr vs Rs 6.10 cr

• Employee benefits expense: Rs 29.33 cr vs Rs 29.51 cr

• Clinical trial expenses / products development expenses: Rs 9.25 cr vs Rs 8.01 cr

• Professional charges: Rs 15.52 cr vs Rs 18.83 cr

• Finance costs: Rs 0.12 cr vs Rs 7.52 cr

• Depreciation and amortisation expense: Rs 2.20 cr vs Rs 2.56 cr

• Other expenses: Rs 11.59 cr vs Rs 11.13 cr

• Total expenses: Rs 77.96 cr vs Rs 83.66 cr

• Profit / (loss) before exceptional item and tax: Rs (24.31) cr vs Rs (75.79) cr

• Exceptional item: Rs - vs Rs -

• Profit / (loss) before tax: Rs (24.31) cr vs Rs (75.79) cr

• Tax expense: Rs 0.08 cr vs Rs 0.06 cr

• Profit / (loss) for the period: Rs (24.39) cr vs Rs (75.85) cr

• Basic and diluted earnings / (loss) per equity share of Rs 1 each: Rs (0.75) vs Rs (2.34)

According to the statement of unaudited consolidated financial results, Sun Pharma Advanced Research Company Ltd reported total revenue from operations of Rs 30.03 cr for the quarter ended 30.09.2026, up from Rs 7.86 cr in the corresponding quarter ended 30.09.2025. Including other income of Rs 23.62 cr (vs Rs 0.01 cr a year earlier), total income rose to Rs 53.65 cr from Rs 7.87 cr.

On the cost side, total expenses for the quarter were Rs 77.96 cr, compared with Rs 83.66 cr in the same quarter last year. Within this, employee benefits expense was Rs 29.33 cr (vs Rs 29.51 cr), clinical trial expenses / products development expenses were Rs 9.25 cr (vs Rs 8.01 cr), and professional charges were Rs 15.52 cr (vs Rs 18.83 cr). Finance costs declined to Rs 0.12 cr from Rs 7.52 cr, while depreciation and amortisation expense stood at Rs 2.20 cr (vs Rs 2.56 cr). Other expenses were Rs 11.59 cr, slightly higher than Rs 11.13 cr a year earlier.

With higher income and lower total expenses, the company’s loss before tax narrowed to Rs (24.31) cr for the quarter ended 30.09.2026 from Rs (75.79) cr in the quarter ended 30.09.2025. After a tax expense of Rs 0.08 cr (vs Rs 0.06 cr), the loss for the period attributable to shareholders was Rs (24.39) cr, compared with Rs (75.85) cr in the year-ago quarter. The basic and diluted earnings / (loss) per equity share of Rs 1 each improved to Rs (0.75) from Rs (2.34), as disclosed in the statement of financial results.